Response to CFTR Modulators in CF Patients Under 18 Years

Launched by SOCIETE FRANCAISE DE LA MUCOVISCIDOSE · Mar 5, 2020

Keywords

ClinConnect Summary

This clinical trial is looking at how well CFTR modulators—medications that help improve the function of a protein important for lung health—work in children with cystic fibrosis (CF) who are under 18 years old. The main goal is to see how the children's lung health changes after one year of treatment with these medications. The study will also monitor their health over the next few years, including how they grow, their quality of life, and any side effects from the medications.

To be eligible for this trial, children must be diagnosed with cystic fibrosis and currently receiving CFTR modulator therapy. Unfortunately, those over 18 years old or those who are pregnant or breastfeeding cannot participate. If your child joins this study, they'll undergo regular check-ups to assess their lung function and overall health, which will help doctors understand how these medications are working and if they are safe for young patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Children with cystic fibrosis under the age of 18 under CFTR modulator therapy
• Exclusion Criteria:
• • Patients with cystic fibrosis without indication for CFTR modulator therapy
• • Patients over the age of 18
• • Pregnant or lactating women